The SURPASS clinical trials included patients with stable cardiovascular disease, though those with unstable or severe cardiovascular conditions were typically excluded
This enables us to always negotiate the best price and pass the savings on to you
5 Not included in the prespecified testing hierarchy for controlling type-I error
Primary results expected 20262027
About the Authors: Sheetal Nijhawan-Long, MD, is a board-certified surgeon and the Medical Director for the Center for Weight Control at Sharon Regional
Lone B Enebo and colleague published a study in The Lancet journal under the title Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 24 mg for weight management: a randomized, controlled, phase 1b trial